Rapt Technologies

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company utilizes its proprietary drug discovery engine to target key drivers of the immune response, specifically focusing on the migration of immune cells. Its lead inflammation candidate, zelnecirnon (RPT193), is a CCR4 antagonist being evaluated for atopic dermatitis and asthma. In oncology, the company is developing tivumecirnon (FLX475), also a CCR4 antagonist, designed to selectively inhibit the migration of regulatory T cells into tumors. RAPT's approach aims to provide the convenience of oral dosing with the efficacy and safety profiles of injectable biologics.